Deal with Roche paves way for near-copy of breast cancer blockbuster
Concerns following event on HAVEN1 trial.
Roche’s top seller faces rival four years after patent expiry
Alecensa part of Roche’s goal of becoming dominant player in NSCLC
Body unconvinced by clinical data for Venclyxto .
Immunotherapy takes on rivals from Roche and BMS.
Tecentriq is latest immunotherapy available on the scheme.
Regulator grants six-month review.
Platform combines morphology analysis, cell counting and cell classification.